AstraZeneca – Pfizer’s bid raises questions over the future of giant pharmaceutical companies
The attempt by Pfizer to achieve the takeover of AstraZeneca with the recommendation of the board of its rival has captured the attention of all those with a direct interest in the result and many others besides.
This in-depth article by Nigel analyses the saga and considers the lessons to be learned from the takeover attempt, examining it against our Five Golden Rules of corporate governance. Covered in the article is the following:
Issues at stake:
- Industry’s strategic issues
- Incentive misalignments
The competing points of view:
- Who shouts loudest?
- Moderate shouters